Aptar Digital Health and SHL Medical partner to improve self-injectable therapies

Aptar Digital Health, a leader in digital health solutions, has partnered with SHL Medical, known for advanced drug delivery systems, to enhance SHL’s connected device technologies using Aptar’s Software as a Medical Device (SaMD) platform. This collaboration aims to provide comprehensive support for patients on injectable therapies, improving their management of diseases.

The partnership will integrate Aptar’s digital health solutions with SHL’s devices, such as the Molly® Connected Cap, to offer enhanced self-administration support through digital means. Aptar’s SaMD platform is tailored to patients’ profiles, disease states, and treatment plans, empowering them throughout their treatment journey.

SHL Medical will recommend Aptar Digital Health as a digital partner, leveraging both companies' strengths to create end-to-end solutions for the pharmaceutical industry. This collaboration is intended to improve the patient experience with self-injection therapies, such as GLP-1, and support adherence to treatment schedules.

Key executives from both companies highlighted the importance of this collaboration in addressing the growing need for home-based treatments and innovating within the drug delivery industry. The partnership will also reinforce Aptar’s portfolio of digital products and services, offering support from pre-prescription to post-prescription stages, including patient activation, disease management platforms, and targeted SaMDs to improve adherence and patient outcomes.